Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by UBS Group AG

UBS Group AG lowered its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) by 9.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 285,532 shares of the company’s stock after selling 31,143 shares during the quarter. UBS Group AG’s holdings in Syndax Pharmaceuticals were worth $6,861,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. increased its holdings in shares of Syndax Pharmaceuticals by 40.7% in the first quarter. JPMorgan Chase & Co. now owns 239,829 shares of the company’s stock valued at $4,168,000 after purchasing an additional 69,356 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Syndax Pharmaceuticals by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 176,391 shares of the company’s stock valued at $3,066,000 after purchasing an additional 9,819 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of Syndax Pharmaceuticals by 58.5% in the first quarter. MetLife Investment Management LLC now owns 27,029 shares of the company’s stock valued at $470,000 after purchasing an additional 9,976 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Syndax Pharmaceuticals by 2.7% in the first quarter. Rhumbline Advisers now owns 58,239 shares of the company’s stock valued at $1,012,000 after purchasing an additional 1,516 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Syndax Pharmaceuticals by 2.9% in the first quarter. BlackRock Inc. now owns 3,798,150 shares of the company’s stock valued at $66,011,000 after purchasing an additional 108,256 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Analysts Set New Price Targets

SNDX has been the subject of several analyst reports. Stifel Nicolaus initiated coverage on Syndax Pharmaceuticals in a research report on Monday, January 30th. They issued a “buy” rating and a $37.00 price objective for the company. HC Wainwright increased their price objective on Syndax Pharmaceuticals from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. StockNews.com upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. JPMorgan Chase & Co. initiated coverage on Syndax Pharmaceuticals in a research report on Tuesday, January 3rd. They issued an “overweight” rating and a $41.00 price objective for the company. Finally, The Goldman Sachs Group increased their price objective on Syndax Pharmaceuticals from $35.00 to $39.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.50.

Syndax Pharmaceuticals Stock Down 3.8 %

SNDX opened at $23.98 on Monday. Syndax Pharmaceuticals, Inc. has a 52 week low of $13.27 and a 52 week high of $29.86. The business has a fifty day simple moving average of $25.84 and a 200-day simple moving average of $24.28. The firm has a market cap of $1.44 billion, a P/E ratio of -1,198.40 and a beta of 1.06.

Insider Transactions at Syndax Pharmaceuticals

In other news, insider Peter Ordentlich sold 25,000 shares of the firm’s stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $25.84, for a total transaction of $646,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Peter Ordentlich sold 25,000 shares of the firm’s stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $25.84, for a total transaction of $646,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Pierre Legault sold 24,000 shares of the stock in a transaction on Thursday, January 12th. The shares were sold at an average price of $26.74, for a total value of $641,760.00. Following the completion of the sale, the director now owns 32,000 shares in the company, valued at $855,680. The disclosure for this sale can be found here. Insiders sold a total of 115,613 shares of company stock worth $3,065,618 over the last ninety days. Company insiders own 6.30% of the company’s stock.

Syndax Pharmaceuticals Company Profile

(Get Rating)

Syndax Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.